| Complementary Roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in Medullary Thyroid Cancer. | |
| | |
MedLine Citation:
|
PMID: 22052128 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Serum calcitonin and carcinoembryonic antigen (CEA) are markers of recurrent or persistent disease in medullary thyroid cancer (MTC). However, conventional imaging often fails to localize metastatic disease. Our aim was to compare fluorine-labeled dihydroxyphenylalanine ((18)F-DOPA) and (18)F-FDG PET/CT with multidetector CT (MDCT) and MRI in recurrent or persistent MTC. METHODS: Nineteen MTC patients with increased calcitonin or CEA on follow-up (mean ± SD, 93 ± 91 mo; range, 4-300 mo) after primary therapy were prospectively imaged with 4 techniques: (18)F-DOPA PET/CT, (18)F-FDG PET/CT, MDCT, and MRI. Images were analyzed for pathologic lesions, which were surgically removed when possible. The correlation between the detection rate for each method and the calcitonin and CEA concentrations and histopathologic findings was investigated. RESULTS: On the basis of histology and follow-up, one or more imaging methods accurately localized metastatic disease in 12 (63%) of 19 patients. The corresponding figures for (18)F-DOPA PET/CT, (18)F-FDG PET/CT, MDCT, and MRI were 11 (58%) of 19, 10 (53%) of 19, 9 (47%) of 19, and 10 (59%) of 17, respectively. Calcitonin and CEA correlated with (18)F-DOPA PET/CT (P = 0.0007 and P = 0.0263, respectively) and (18)F-FDG PET/CT findings (both P < 0.0001). In patients with an unstable calcitonin doubling time (n = 8), (18)F-DOPA and (18)F-FDG PET/CT were equally sensitive. In contrast, for patients with an unstable CEA doubling time (n = 4), (18)F-FDG PET/CT was more accurate. CONCLUSION: For most MTC patients with occult disease, (18)F-DOPA PET/CT accurately detects metastases. In patients with an unstable calcitonin level, (18)F-DOPA PET/CT and (18)F-FDG PET/CT are complementary. For patients with an unstable CEA doubling time, (18)F-FDG PET/CT may be more feasible. MRI is sensitive but has the highest rate of false-positive results. |
| | |
Authors:
|
Saila Kauhanen; Camilla Schalin-Jäntti; Marko Seppänen; Sami Kajander; Sami Virtanen; Jukka Schildt; Irina Lisinen; Aapo Ahonen; Ilkka Heiskanen; Mika Väisänen; Johanna Arola; Pirkko Korsoff; Tapani Ebeling; Timo Sane; Heikki Minn; Matti J Välimäki; Pirjo Nuutila |
Related Documents
:
|
21591008 - Hepatic fat quantification using chemical shift mr imaging and mr spectroscopy in the p... 6375288 - Stereotactic ct scan applied to stereotactic thalamotomy and biopsy. 22009418 - Dual-time point positron emission tomography findings of benign mediastinal lymph nodes... 2666368 - Heavy charged-particle stereotactic radiosurgery: cerebral angiography and ct in the tr... 21591008 - Hepatic fat quantification using chemical shift mr imaging and mr spectroscopy in the p... 15383968 - Functional imaging of parotid glands: diffusion-weighted echo-planar mri before and aft... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-11-3 |
Journal Detail:
|
Title: Journal of nuclear medicine : official publication, Society of Nuclear Medicine Volume: - ISSN: 1535-5667 ISO Abbreviation: - Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-11-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0217410 Medline TA: J Nucl Med Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Turku PET Centre, Turku University Hospital, Turku, Finland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Imaging in Sarcoma.
Next Document: Smartphone App Use Among Medical Providers in ACGME Training Programs.